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Abstract
Defining the components of an HIV immunogen that could induce effective CD8+ T cell re-
sponses is critical to vaccine development. We addressed this question by investigating the
viral targets of CD8+ T cells that potently inhibit HIV replication in vitro, as this is highly pre-
dictive of virus control in vivo. We observed broad and potent ex vivo CD8+ T cell-mediated
viral inhibitory activity against a panel of HIV isolates among viremic controllers (VC, viral
loads<5000 copies/ml), in contrast to unselected HIV-infected HIV Vaccine trials Network
(HVTN) participants. Viral inhibition of clade-matched HIV isolates was strongly correlated
with the frequency of CD8+ T cells targeting vulnerable regions within Gag, Pol, Nef and Vif
that had been identified in an independent study of nearly 1000 chronically infected individu-
als. These vulnerable and so-called “beneficial” regions were of low entropy overall, yet sev-
eral were not predicted by stringent conservation algorithms. Consistent with this, stronger
inhibition of clade-matched than mismatched viruses was observed in the majority of sub-
jects, indicating better targeting of clade-specific than conserved epitopes. The magnitude
of CD8+ T cell responses to beneficial regions, together with viral entropy and HLA class I
genotype, explained up to 59% of the variation in viral inhibitory activity, with magnitude of
the T cell response making the strongest unique contribution. However, beneficial regions
were infrequently targeted by CD8+ T cells elicited by vaccines encoding full-length HIV
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proteins, when the latter were administered to healthy volunteers and HIV-positive ART-treat-
ed subjects, suggesting that immunodominance hierarchies undermine effective anti-HIV
CD8+ T cell responses. Taken together, our data support HIV immunogen design that is
based on systematic selection of empirically defined vulnerable regions within the viral prote-
ome, with exclusion of immunodominant decoy epitopes that are irrelevant for HIV control.
Author Summary
Attempts to develop an HIV vaccine that elicits potent cell-mediated immunity have so far
been unsuccessful. This is due in part to the use of immunogens that appear to recapitulate
responses induced naturally by HIV that are, at best, partially effective. We previously
showed that the capacity of CD8+ T cells from patients to block HIV replication in culture
is strongly correlated with HIV control in vivo, therefore, we investigated the virological
determinants of potent CD8+ T cell inhibitory activity. We observed that CD8+ T cells
from patients with naturally low plasma viral loads (viremic controllers) were better able
to inhibit the replication of diverse HIV strains in vitro than CD8+ T cells from HIV-non-
controller patients. Importantly, we also found that the potency of the antiviral activity in
the latter group was strongly correlated with recognition of selected regions across the
viral proteome that are critical to viral fitness. Vaccines that encode full-length viral pro-
teins rarely elicited responses to these vulnerable regions. Taken together, our results pro-
vide insight into the characteristics of effective cell-mediated immune responses against
HIV and how these may inform the design of better immunogens.
Introduction
Only two HIV vaccines designed to elicit protective T cell responses have reached clinical effi-
cacy testing, both with disappointing results [1][2][3]. The reasons for this are not completely
understood, despite much accumulated knowledge regarding the characteristics of cell-mediat-
ed immune responses associated with HIV and SIV control. The limited magnitude and
breadth of vaccine-induced T cell responses, particularly when compared with responses to
similar vaccines in non-human primate models, the modest cytotoxic capacity of CD8+ T cells,
waning of responses over time, bias towards targeting of more variable regions of the viral pro-
teome and the modest immunogenicity of the vaccine vector regimens are all likely contribut-
ing factors [2][4][5][6][7][8]. A critical first step towards addressing this is to determine
whether the antiviral efficacy of CD8+ T cells is a function of their specificity.
The HVTN 502 (Step) and 503 (Phambili) trials were a test-of-concept for induction of pro-
tective T cell responses that collectively evaluated Merck’s trivalent adenovirus type 5 HIV-1
Gag/Pol/Nef vaccine in*3800 subjects at high risk of HIV acquisition [1][9]. Post-hoc analy-
ses of HVTN 502 have shown that individuals in whom vaccine-induced responses targeted
3 epitopes in Gag achieved a lower viral load after HIV infection than subjects without Gag
responses; it is striking, however, that these subjects were a small minority among the vaccinees
(<7%) [6]. While this confirms several observational studies that showed an association be-
tween HIV control and preferential recognition of Gag epitopes [10][11], the question remains
as to why vaccines that express full-length Gag proteins have so far failed to induce responses
that can impact on HIV replication after infection. The answer may be two-fold: first, immuno-
dominance hierarchies of the T cell responses elicited by these vaccines often mimic those of
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natural infection, with ‘hotspots’ in variable and least vulnerable regions of the viral proteome
[12]; second, even within Gag and other conserved proteins, not all epitopes are equal in terms
of vulnerability to immune pressure, or ‘fragility’, which is defined by the capacity to maintain
function in the face of genetic mutations [13]. Thus, the efficacy of cell-mediated immune re-
sponses may depend on the specific epitopes targeted, both within and outside Gag. This was
demonstrated in an observational study of 950 clade B- and C-infected individuals, in whom
responses to overlapping peptides (OLP) spanning the entire viral proteome were systematical-
ly analysed [14]. A ‘protective ratio’ (PR) was calculated for each OLP from the ratio of the me-
dian viral load in subjects who failed to respond to the OLP to responders. OLP with a
protective ratio>1 were defined as ‘beneficial’. Of note, Gag proteins contained the majority of
the beneficial regions, though not all of them, and also contained regions that were not targeted
by protective responses. Together, these data support the ‘decoy’ hypothesis, which proposes
that certain epitopes within the viral proteome elicit dominant yet irrelevant responses that
serve to undermine effective targeting of regions of vulnerability [15]. This question will only
be adequately addressed by clinical testing of rationally designed immunogens based on ‘bene-
ficial’ regions, as proposed by Rolland et al. and Mothe et al. [15][14].
Aside from identifying specific beneficial targets, the precise mechanisms and effector func-
tions of antiviral T cell responses that underlie heterogeneity in HIV control among infected
individuals need to be defined. We showed in a prospective study that CD8+ T cell viral inhibi-
tory activity in vitro strongly correlated with HIV control in vivo, reflected in both viral load
set-point and CD4+ cell decline over time [16]. This indicates that CD8+ T cell viral inhibitory
activity is expressed on a continuum and is not a discrete function that is unique to HIV con-
trollers with protective HLA alleles, providing scope for induction of effective CD8+ T cell re-
sponses by vaccination of subjects who do not have a favourable genotype. Viral inhibition
assays that use polyclonal T cell populations provide a composite measure of lytic and non-
lytic activity of all circulating HIV-specific CD8+ T cells, which may be heterogeneous in their
functional capacity [17][18][19][20][21][22]. This activity is detectable in acute infection in a
minority but rapidly wanes, likely as a result of viral escape and / or functional impairment
[23][24][21][25]. Low level activity has also been detected in HIV-naïve recipients of DNA and
adenovirus type 5-vectored vaccines encoding full-length HIV proteins even though such vac-
cines are capable of eliciting substantial numbers of Gag- and Pol-specific cytokine-secreting T
cells [23][26][3]. These observations underscore the need for better understanding of the fac-
tors that determine the potency of CD8+ T cell viral inhibitory activity.
We also showed previously that CD8+ T cell viral inhibition in chronically infected individ-
uals did not correlate with the total magnitude of IFN-γ-positive T cell response to any single
HIV protein, including Gag [16]. This was surprising, given the known associations between
Gag responses and HIV control, and led us to propose the hypothesis that potent viral inhibi-
tion depends on preferential targeting of selected regions that are not limited to Gag nor pre-
dicted by conservation score alone. We hypothesised that responses to such critical regions are
generally subdominant and that this may explain the lack of efficacy of T cell-inducing vac-
cines. To this end, we investigated CD8+ T cell-mediated inhibitory activity in a subset of
HIV-positive HVTN 502 and 503 vaccine trial participants. This comprised recipients of both
the vaccine and placebo who were sampled at the same time during early HIV infection (1
year). They were naïve to antiretroviral therapy (ART), with CD4 cell counts>350 cells/μl,
and were not selected for low virus loads or protective HLA class I alleles. In parallel, we stud-
ied ART-naïve subjects who showed spontaneous long-term control of HIV, with plasma viral
loads consistently<5000 copies/ml (viremic controllers, VC). They were sampled later in in-
fection (median 4.5 years) and were included as a reference cohort, as potent CD8+ T cell anti-
viral activity has been reported in such individuals [23][26][16].
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Results
Limited potency and breadth of CD8+ T cell antiviral inhibitory activity in
the majority of HIV-positive vaccine and placebo recipients
CD8+ T cell antiviral activity was measured in 34 HIV-positive HVTN 502 & 503 trial partici-
pants, who were infected with clade B and C viruses respectively. They were aligned for dura-
tion of infection, early post-infection viral load and CD4+ cell counts. Only a minority had
either a protective HLA class I allele (n = 7, 20%) or evidence of spontaneous viremia control,
indicated by plasma viral loads consistently below 5000 copies/ml (n = 5, 15%) (Table 1). We
included both vaccinees and placebos in order to maximise the number of subjects with sam-
ples available for analysis. Fourteen VC with viral loads<5000 copies/ml were studied in paral-
lel as a reference cohort. The estimated duration of HIV infection in latter ranged from 1–11
years. Six (43%) had a protective HLA class I allele and all were presumed clade B-infected
(Table 2). The inclusion of clade B and C cohorts enabled us to ascertain whether the associa-
tion between CD8+ T cell inhibitory activity and HIV control was clade-independent, as sug-
gested by our previous results [16]. However, a major goal of this study was to explore the
extent of cross-clade inhibition (breadth) using a panel of laboratory-adapted and primary
HIV isolates representing clades A, B and C strains, as this had not been systematically exam-
ined in HIV-positive individuals before. CD8+ T cells from HIV-positive HVTN 502 & 503
participants were tested according to PBMC availability, using at least one clade B and one
clade C virus, while all VC were tested against five viral isolates (S1 Table). Among the HIV-
positive trial participants in whom viral inhibitory activity against a clade-matched virus was
analysed at a CD8+/CD4+ cell ratio of 2:1, it was not significantly different between vaccinees
(n = 20) and placebo (n = 8) recipients (ranges 0–87% vs. 0–93%, p = 0.32; Fig. 1A). Because no
difference was observed, analyses presented in the main were performed by combining data
Table 1. Characteristics of HVTN 502 and 503 trial participants.
502 503 p value
N 20 16
Sex, male (%) 100 31 -
Age, years 30 (23–35) 23 (22–28) 0.07
Known duration of
infection (days)
364 (363–365) 370 (364–375) 0.10
CD4+ T cell count, cells/
μl*
633 (487–671) 559 (463–651) 0.46
Plasma viral load at 3
months, log10 copies/ml
4.2 (3.3–4.7) 4.4 (3.6–5.2) 0.31
Known protective alleles
(n) §
4 3 -
Clade
B 19/20 0/16
C 0/20 13/16
Other 1/20 2/16 (CA, CB)
Not deﬁned 0/20 1/16
Data shown are median values (interquartile range) unless otherwise indicated.
* At time of sampling
§ HLA-B*27, B51, B*5701/03, B*5801 and B*8101
doi:10.1371/journal.ppat.1004658.t001
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from both the vaccinee and placebo groups. However, the vaccinees were also analysed inde-
pendently as they accounted for two-thirds of the HVTN cohorts. The data are shown in Supple-
mentary Results, S1 Text. Whether data were combined or independent, the results were similar.
Inhibition of a clade-matched virus was significantly higher among VC at CD8+/CD4+ T cell
ratios of both 2:1 (medians 85% and 37% respectively, p<0.0001) (Fig. 1B) and 1:10 (medians
61% and 0% respectively, p<0.0001 (Fig. 1C). VC also showed more potent cross-clade inhibi-
tion than HVTN 502 participants when tested using a clade C virus (CD8+/CD4+ T cell ratio
of 2:1—medians 60% vs. 14%, p = 0.002) (Fig. 1D). These differences remained significant
when the placebos were excluded from the analyses (Supplementary Results, S1 Text). Cross-
clade activity was analysed further using at least 3 viruses in 14 HVTN 502 & 503 participants
and 14 VC. Differences in the potency and breadth of CD8+ T cell-mediated inhibitory re-
sponses in these groups are highlighted in the heatmap (Fig. 1E).
We have previously reported a significant inverse relationship between CD8+ T cell antivi-
ral activity measured 6 months post-infection in a primary HIV infection cohort and viral load
set-point, a known predictor of the rate of progression to AIDS [16]. In the present study,
CD8+ T cell inhibitory activity was measured later. Nevertheless, there was still a significant
inverse correlation between CD8+ T cell inhibition of a clade-matched virus and viral load set-
point (which was attained within 100 days of infection in the HVTN trial participants) or cur-
rent viral load in the VC (r = -0.49, p = 0.0009, S1 Fig.).
CD8+ T cell antiviral potency is strongly associated with targeting of
known ‘beneficial’ regions
The finding that HIV-positive trial participants showed less potent inhibition of a clade-
matched virus isolate than VC was consistent with results from previous studies of early in-
fected individuals [16][24]. Here, we extended these observations to clade-mismatched viruses.
The broader CD8+ T cell inhibitory responses in VC suggested that they preferentially recog-
nised conserved viral epitopes. However, when examining responses within the groups, we
observed more potent inhibition of clade-matched than mismatched viruses in VC and HIV-
positive trial participants alike. This indicated that CD8+ T cells targeting clade-specific viral
epitopes must contribute to the overall potency of the response. To investigate this further, we
used ex vivo IFN-γ Elispot assays to measure the magnitude of responses to two sets of overlap-
ping 15-mer peptides. The first corresponded to the beneficial regions that were defined by
Mothe et al. in clade B and clade C-infected populations (S2 and S3 Tables) and the second to a
Table 2. Characteristics of Viremic Controller subjects.
N 14
Sex, male (%) 40
Age, years—median (IQR) 45 (37–49)
Known duration of infection, years* - median (IQR) 4.5 (2.25–6.25)
CD4+ T cell count, cells/μl* - median (IQR) 721 (672–885)
Plasma viral load, log10 copies/ml* - median (IQR) 3.1 (2.9–3.3)
Known protective alleles, n § 6
Clade—B# 14/14
* At time of sampling
§ HLA-B*27, B51, B*5701/03, B*5801 and B*8101
# Presumed clade due to geographical location
doi:10.1371/journal.ppat.1004658.t002
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Fig 1. CD8+ T cell antiviral inhibitory activity in HIV-positive HVTN subjects and HIV viremic controllers. A. CD8+ T cell mediated-inhibition of a clade-
matched virus was measured in 28 HIV-positive HVTN 502 & 503 subjects at a CD8+/CD4+ cell ratio of 2:1. Eight subjects are not shown as cell recoveries
allowed testing at a CD8+/CD4+ cell ratio of 1:1 only (n = 6, see S1 Table) or CD4+ cells did not survive HIV superinfection (n = 2). Data are stratified by
vaccine or placebo allocation. B-D.CD8+ T cells from 16 HVTN 502 participants and 14 VC (all infected with clade B viruses) were tested for inhibition of a
clade B HIV isolate at CD8+/CD4+ cell ratios of 2:1 (B) and 1:10 (C) or inhibition of a clade C isolate, ES X-1936 (CD8+/CD4+ = 2:1) (D). Placebos are
indicated by open circles. In all graphs, horizontal lines indicate medians. E. Heatmap showing potency and breadth of CD8+ T cell-mediated inhibition
(CD8+/CD4+ cells = 2:1) among 14 viremic controllers and 14 HIV-positive HVTN 502 and 503 participants for whom at least 3 virus isolates were tested.
Viral inhibition was measured on day 6 for all viruses except A2 (RW93024), for which it was measured on day 3 due its different replication kinetics (see
Methods). Darker colour indicates higher inhibition; scale 0–100%, grading—20%.
doi:10.1371/journal.ppat.1004658.g001
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set of ‘conserved elements’ (CE) peptides that were originally defined by Rolland et al. and con-
sisted of 7 regions in Gag p24 (S4 Table) [14][27][28]. The peptides representing beneficial re-
gions were constituted in pools according to their previously defined protective ratio, with the
first pool of each protein containing the peptides with the highest protective ratio (higher num-
ber indicating lower viral load in responders compared with non-responders) [14]. CE peptides
were divided into pools A & B, also in accordance with previously observed associations with
low virus loads [29] (S4 Table). To match their infecting clade, VC and HVTN 502 participants
were tested with a peptide set representing beneficial regions in Clade B and HVTN 503 sub-
jects were tested with the Clade C beneficial peptide set. All three groups were tested with the
same CE peptide set. For all Elispot assays, CD8+ T cells were obtained from the same sample
as that used in the viral inhibition assay (except for 2 VC in whom it was necessary to use an
additional sample obtained within 1 year of the original bleed). Summed frequencies of IFN-γ-
producing CD8+ T cells targeting the beneficial and CE peptides are shown in Fig. 2. The medi-
an response to beneficial peptides was 190 and 262 SFU/million CD8+ T cells for HVTN 502
and 503 groups respectively and 210 SFU/million CD8+ T cells for the VC (Fig. 2A). The medi-
an response to the CE peptides was 60 SFU/million CD8+ T cells for the combined HVTN
groups and 35 SFU/million CD8+ T cells for the VC (Fig. 2B). These differences were not sta-
tistically significant, nor were there significant differences between vaccinees and placebos in
terms of the magnitude of response to either beneficial (medians 198 vs. 415 SFU/million
CD8+ T cells, p = 0.99) or CE peptides (medians 55 vs 60 SFU/million CD8+ T cells, p = 0.6).
This group of VC did not show significantly higher responses to beneficial or CE peptides
than the HVTN subjects. This was unexpected in the light of previous reports but likely re-
flected the longer duration of infection (median 4.5 years vs. 1 year), which may be associated
with loss of responses to epitopes within the regions studied, due to mutational escape [14][29]
[30][31][32]. For example, the two VC who were HLA-B5701-positive did not make detect-
able responses to the beneficial or CE peptide pools that contained immunodominant Gag epi-
topes restricted by this allele (TW10 and KF11).
We next explored the relationship between virus inhibition and the magnitude of CD8+ T
cell responses to the beneficial and CE regions in the HVTN subjects. We observed a strong
correlation between the magnitude of T cell responses to beneficial regions and CD8+ T cell-
mediated inhibition of a clade-matched virus (r = 0.69, p = 0.0001 for a CD8+/CD4+ cell ratio
of 2:1) (Fig. 2C). This relationship was also confirmed using a lower CD8+/CD4+ cell ratio
of 1:1 (r = 0.5, p = 0.01) and importantly, was maintained after removal of subjects with pro-
tective HLA class I alleles (HLA-B27, B51, B5701/03, B5801, B81) (r = 0.71, p = 0.0005)
(Fig. 2D). Furthermore, these correlations remained statistically significant after exclusion of
placebos (Supplementary Results, S1 Text). Taken together, these analyses suggested that
CD8+ T cell viral inhibition of>85% (i.e. the median response in VC) was associated with a
beneficial peptide response threshold of*1300 SFU/million CD8+ T cells. Additional support
for the relationship between CD8+ T cell viral inhibition and magnitude of T cell responses
to beneficial regions was obtained in a subset of subjects (n = 15) in which individual peptides
were tested in cultured Elispot assays. The highest viral inhibition also correlated with the
higher magnitude T cell responses to individual beneficial peptides (r = 0.61, p = 0.02, Fig. 2E).
Unexpectedly, there was a weaker association between the magnitude of T cell responses to the
conserved elements pools and CD8+ T cell viral inhibition (r = 0.41, p = 0.04) (Fig. 2F). This
positive relationship was also maintained after exclusion of placebos (Supplementary Results,
S1 Text) and was largely driven by responses to the conserved elements pool B, containing
peptides spanning CE 4, 5 and 6.
We also analysed the frequency of T cell responses to the total HIV proteome as these had
been measured previously by intracellular staining for IFN-γ (at a median of 5 weeks after HIV
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infection) after stimulation of PBMC with clade B consensus potential T cell epitope (PTE)
peptide sets [2][30]. These were selected to optimise the detection of CD8+ T cell responses to
circulating viruses and thus ensure accurate measurement of the maximum response [33]. The
total proteome response (median) was 1.81% CD8+ T cells (Fig. 3A), with no significant differ-
ence between HVTN 502/503 vaccinees and placebos (median 2.1% and 1.5% of CD8+ T cells
respectively, p = 0.23), which is similar to data obtained from chronic infection cohorts [31].
There was no correlation between CD8+ T cell antiviral activity and responses to the whole
Fig 2. CD8+ T cell inhibitory activity and targeting of beneficial regions and conserved elements within the HIV proteome.CD8+ T cell responses to
peptides based on (A) clade-specific ‘beneficial’ regions and (B) Gag ‘conserved elements’ were measured by IFN-γ Elispot assays. Net responses
(background subtracted) are shown; values for negative controls were median (IQR)– 10 (0–15) SFU/million CD8+ T cells. Horizontal lines indicate median
values. HVTN vaccinees and placebos are shown as closed and open symbols respectively inA. In B, HVTN subjects are grouped together and represented
as follows: HVTN 502—vaccinees, black closed circles, placebos, black open circles; HVTN 503—vaccinees, grey closed circles, placebos, grey open
circles. VC are shown as triangles in A & B. Six HVTN 503 subjects were excluded as viral subtype data were not confirmed at the time of the analysis. One
VC subject was excluded as no sample was available for Elispot assay. C. Correlation between CD8+ T cell inhibition of a clade-matched virus (CD8+/CD4+
cell ratio = 2:1) and magnitude of CD8+ T cell responses to beneficial peptides (summed) in 26 HVTN subjects.D. The analysis was repeated after removal
of subjects with protective HLA class I alleles and (E) with short-term cell lines expanded from CD8+ T cells recovered from Elispot assays in 15 subjects that
were then tested with individual peptides from the pools which elicited a response in the ex vivo Elispot assay. For C-F: closed circles—502 and 503
vaccinees; open circles—502 and 503 placebos. F. Correlation between CD8+ T cell inhibition (2:1 ratio) of a clade-matched virus and magnitude of CD8+ T
cell responses to conserved elements peptides in 27 HVTN subjects (left panel—sum of all CE peptides, middle—CE pool A, right—CE pool B).
doi:10.1371/journal.ppat.1004658.g002
Potent Subdominant Anti-HIV CD8+ T Cells in Infection and Vaccination
PLOS Pathogens | DOI:10.1371/journal.ppat.1004658 February 27, 2015 8 / 22
proteome, either for HVTN subjects as a whole (r = 0.14, p = 0.5) (Fig. 3B) or for the vaccinees
only (Supplementary Results, S1 Text).
Variation in CD8+ T cell antiviral activity is best explained by the
magnitude of responses to beneficial peptides
In view of the strong correlation between CD8+ T cell antiviral activity and recognition of ben-
eficial peptides, we explored this relationship further using a series of univariate and multivari-
able regression models, with CD8+ T cell antiviral activity as the dependent variable. We
investigated associations with the following independent variables: 1) the Shannon entropy
score for each beneficial region as a measure of its variability at the population level; 2) the
magnitude of responses to beneficial regions (‘total beneficial’ response); 3) the magnitude of
the Gag component of the beneficial regions (‘beneficial Gag’ response), in order to ascertain
how much this contributed to the total beneficial response; 4) the magnitude of responses to
CE peptides; 5) the ratio of magnitude of responses to beneficial regions to the total proteome
response (relative magnitude or immunodominance) and 6) the presence of protective (‘good’)
or non-protective (‘bad’) HLA class I alleles.
For our first set of models, entropy was used as the primary independent (or predictor) vari-
able of interest since both the beneficial regions and CE regions were largely derived from con-
served, i.e. low entropy regions in the viral proteome [14][28]. Thus, our first regression model
included entropy as the only independent variable. Total beneficial responses, beneficial Gag
responses or CE responses were then each added separately to this baseline model to ascertain
whether they improved the fit of the model (as captured by a change in the model r2) and,
thus, whether they were independently associated with CD8+ T cell activity. Entropy alone ex-
plained 13.5% of the variance in inhibition. Addition of the total beneficial response or the ben-
eficial Gag response each improved the fit of the model (by 46% and 24% respectively) and the
contribution of each of these was statistically significant (Table 3). By contrast, addition of the
CE response had no effect (increase in model r2 of 0.1%).
We also constructed three multivariable regression models that included various combina-
tions of the following factors: magnitude of total beneficial responses, relative magnitude or
Fig 3. CD8+ T cell responses to PTE peptides based on to the entire HIV proteomewere measured in
HIV-positive HVTN participants (502—vaccinees, black closed circles; placebos, black open circles)
and (503—vaccinees, grey closed circles; placebos, grey open circles) at week 5 post-infection by
intracellular staining for IFN-γ. A. B. Correlation between CD8+ T cell inhibition (CD8+/CD4+ cell ratio =
2:1) of a clade-matched virus and magnitude of CD8+ T cell response to the entire HIV proteome, colour-
coded as indicated in A. Five subjects are not shown in B, due to lack of viral inhibition data for the 2:1 ratio.
doi:10.1371/journal.ppat.1004658.g003
Potent Subdominant Anti-HIV CD8+ T Cells in Infection and Vaccination
PLOS Pathogens | DOI:10.1371/journal.ppat.1004658 February 27, 2015 9 / 22
entropy of beneficial regions and good or bad HLA class I alleles. The combinations of covari-
ates for these models were chosen to allow us to investigate several potential pathways for any
associations, based on hypothesised interactions between absolute and relative magnitude of
responses and between certain HLA alleles and entropy of epitopes restricted by these alleles.
These models explained 39–49% of the variance in CD8+ T cell inhibition and all were signifi-
cant as a whole. However, in each case the magnitude of the response to beneficial regions
made the strongest unique contribution whereas the contribution of the other variables was
not statistically significant (Table 4).
Responses to vaccines encoding full-length HIV proteins are skewed
towards non-beneficial regions of the viral proteome
Given that responses to beneficial regions were subdominant in HIV-infected individuals, we
next investigated whether this was also the case for responses that are primed in HIV-naïve in-
dividuals by vaccines encoding full-length HIV proteins. Data on responses that developed
post-vaccination and prior to HIV acquisition were available for 13/20 of the HVTN 502 trial
participants in this analysis (sampled 4 weeks after the second vaccination) [6]. We compared
the magnitudes of vaccine-induced responses to peptides spanning the entire Gag/Pol/Nef im-
munogen with beneficial and CE regions. Vaccination induced responses to beneficial regions
in 5/13 patients and to CE regions 3/13 patients, while no response to any of these regions was
detected in 5 subjects. Overall, vaccine-induced responses to beneficial regions accounted for a
median (range) of 0% (0–43%) of the response to the entire immunogen in these subjects, de-
spite representing 36% of the immunogen sequence (Fig. 4A).
Finally, we investigated whether natural immunodominance hierarchies were maintained
or altered following the administration of a Gag immunogen as a therapeutic vaccine in chron-
ic HIV infection. We mapped T cell responses to beneficial and non-beneficial regions before
Table 3. Univariate linear regression models to investigate associations between entropy, beneﬁcial and conserved elements responses and %
inhibition (dependent variable).
Model 1 Model 2 Model 3 Model 4
Entropy 152.8 144.2 126.8 142.8
[-146.7–452.3] [31.1–257.3] [15.1–268.7] [-99.1–384.7]
p = 0.08 p = 0.02 p = 0.09 p = 0.08
Total beneﬁcial response - 0.03 - -
[0.02–0.04]
p <0.001
Beneﬁcial Gag response - - 0.03 -
[0.01–0.05]
p = 0.01
Conserved elements response - - - 0.001
[-0.02–0.02]
p = 0.91
Model r2 0.135 0.594 0.372 0.136
Values shown are parameter estimates [95% conﬁdence intervals] for each model.
All models: entropy refers to Shannon entropy score for beneﬁcial peptides
Model 2: total beneﬁcial response = sum of responses to beneﬁcial peptide pools
Model 3: beneﬁcial Gag response = sum of responses to beneﬁcial Gag pools only
Model 4: conserved elements (CE) response = sum of responses to CE pools
doi:10.1371/journal.ppat.1004658.t003
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and after vaccination with an immunogen, ‘HIVA’ comprising full-length Gag p24/p17 se-
quences fused to a multiepitope string, delivered as a modified vaccinia virus Ankara-vectored
vaccine to chronic ART-treated HIV-positive subjects with suppressed viremia [34][35]. Epi-
tope mapping was performed in 9 subjects using overlapping 15-mers spanning p24 and p17, to-
gether with optimal 8–10-mer peptides for epitopes that had been defined previously (Table 5)
[36]. We confined our analysis to responses to the Gag component of the immunogen, since the
epitope string was, by definition, designed to focus responses on selected regions of the proteome.
Prior to vaccination, the magnitude of summed responses to beneficial regions was lower than
for non-beneficial Gag regions, although the difference was not statistically significant (median
205 and 615 SFU/million PBMC respectively, p = 0.27). MVA.HIVA vaccination significantly
boosted T cell responses to the beneficial Gag regions (median change +150 SFU/million PBMC,
p = 0.03). However, responses to non-beneficial Gag regions were preferentially expanded (medi-
an change +845 SFU/million PBMC, p = 0.004) (Fig. 4B, Table 5). Taken together, these data sug-
gest that vaccines encoding full- or near full-length HIV proteins mimic natural HIV infection by
eliciting responses that are biased towards non-beneficial targets, regardless of whether they are
administered to HIV-naïve or primed individuals.
Discussion
The lack of a reliable correlate of protective immunity against HIV is a significant obstacle to
systematic evaluation of vaccine candidates. Consequently, efforts to develop a T cell-based
Table 4. Multivariate linear regression models to investigate associations between beneﬁcial
responses, entropy, HLA alleles and % inhibition (dependent variable).
Parameter estimate 95% CI P
Model 1
Constant 4.97 -33.1–43 0.78
Magnitude 0.03 -0.004–0.06 0.08
Entropy 125.42 -47.7–299 0.14
Ratio of protective / total response 92.55 -359.9–545 0.67
Model r2 0.39
Model 2
Constant 5.87 -26–37.7 0.70
Magnitude 0.03 0.01–0.05 0.003
Entropy 130.89 -22.8–284.6 0.09
Good allele* -2.72 -29.5–24 0.83
Model r2 0.47
Model 3
Constant 4.44 -27.1–35.9 0.77
Magnitude 0.03 0.01–0.05 0.002
Entropy 121.9 -21.9–265.7 0.09
Bad Allele§ 9.25 -14.4–32.9 0.42
Model r2 0.49
In each model, magnitude = total beneﬁcial response (sum of responses to beneﬁcial peptide pools)
Ratio of protective / total response = total beneﬁcial response / total proteome response (both deﬁned as
IFN-γ+ cells/million CD8+ T cells)
* HLA-B*27, B*51, B*5701, B*5801, B*81
§ HLA-B*35 (Py), HLA-B*53
doi:10.1371/journal.ppat.1004658.t004
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vaccine have focused broadly on recapitulating the immunological phenotype of HIV control-
lers, using immunogens incorporating near-complete gene sequences for many proteins. Re-
cently, there has been greater emphasis on rationally designed immunogens, in particular,
those that aim to maximise coverage of variable viral epitopes (mosaics) or avoid them alto-
gether (conserved regions) [15][37][38][39][8]. CD8+ T cell-mediated viral inhibition was
found to correlate with the frequency of T cells targeting conserved epitopes in HIV-uninfected
vaccinees [8][40]. However, no vaccine candidate has yet been shown to elicit viral inhibitory
activity of similar potency to that observed in HIV controllers. Here, we report that the total
Fig 4. Vaccines based on full-length protein immunogens elicit subdominant responses to beneficial
regions and / or conserved elements within the HIV proteome. A. Post-vaccination, pre-infection CD8+ T
cell responses to overlapping peptides spanning the MRK Ad5 Gag/Pol/Nef immunogen determined by IFN-γ
Elispot assay in 13 HVTN 502 participants (dark blue bars) (4 weeks post-second vaccination). Responses to
beneficial regions and Gag conserved elements within the immunogen are indicated by magenta and
turquoise bars respectively. B. Pre- and post-vaccination responses to beneficial and non-beneficial regions
within Gag determined by IFN-γ Elispot assay in 9 HIV-positive subjects after therapeutic vaccination with
MVA.HIVA.
doi:10.1371/journal.ppat.1004658.g004
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viral inhibitory capacity of anti-HIV CD8+ T cells is highly dependent on their specificity and
we provide a mechanism to explain why conventional HIV immunogens elicit largely ineffec-
tive CD8+ T cell responses.
We reported previously that ex vivo CD8+ T cell-mediated viral inhibitory activity is in-
versely correlated with viral load set-point; we confirmed this finding here in genetically unre-
lated cohorts infected with different viruses [16]. While this is consistent with well-established
associations between primary CD8+ T cell responses to HIV-1 and control of acute viraemia
[41][42][32][43], the time interval between attainment of viral load set-point and sampling for
the viral inhibition assay was longer in the present study, thus we cannot rule out the possibility
that early control of viraemia was the cause rather than the consequence of the level of antiviral
activity. It is also conceivable that a viral inhibition ‘set-point’ is attained soon after infection;
this could explain the findings of Lecuroux et al., who reported that most HIV-infected individ-
uals showed modest CD8+ T cell inhibitory activity throughout acute and early infection [24].
Nevertheless, our data give insight into the level of inhibitory activity that might be used as a
benchmark to assess vaccine candidates: for example, inhibition of a clade-matched virus by
85% (observed in 50% of VC subjects but only 7% of HVTN trial participants) was associated
with a median viral load of* 2000 copies/ml. This suggests that the bar must be set very high
if such assays are to be used to identify vaccine strategies that could clear HIV infection or re-
duce viral loads to undetectable levels [44].
We report for the first time, to our knowledge, that the breadth of inhibitory activity, indi-
cated by inhibition of clade-mismatched viruses, was significantly greater in VC than subjects
with uncontrolled viraemia. This suggested two non-mutually exclusive explanations: enrich-
ment of the HIV-specific repertoire in VC for T cells recognising conserved epitopes and / or
high frequencies of circulating cross-reactive CD8+ T cells that can tolerate epitope variation.
However, potent clade-specific viral inhibitory activity, together with differential inhibition of
diverse viruses was evident in both study groups. This led us to hypothesise that factors other
than epitope conservation must play a role in the control of viral replication. We found that
CD8+ T cell antiviral activity in HVTN subjects was highly correlated with the frequency of
Table 5. Distribution of responses to Gag peptides in HIV-positive MVA.HIVA vaccinees.
Peptide in beneﬁcial region in Gag Peptide in non-beneﬁcial region in Gag
Subject Response(SFU/106 PBMC) Pre Post Response(SFU/106 PBMC) Pre Post
001 SLFNTVATL 775 1070 AEQATQEVKNW 460 1090
KDTKEALDKIEEIQN 115 715
004 WASRELERF 10 90
006 SLFNTVATL 205 295 LNKIVRMYSPV 995 1010
SVLSGGKLDAWEKIR 915 1085
009 KIRLRPGGK 520 1690 SPRTLNAW 115 360
ACQGVGGPGHK 540 1055
010 LVQNANPDCKSILRA 15 710
012 KIRLRPGGKKKYRLK 145 380 LVQNANPDCKSILRA 105 320
GDIYKRWII 1210 2445
018 TQEVKNWMTETTLVQ 70 20
021 SLFNTVATL 120 180
GGKKKYKL 200 290
022 VRMYSPVSILDIRQG 185 595 ISPRTLNAW 985 1750
FRDYVDRFFK 250 630
doi:10.1371/journal.ppat.1004658.t005
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CD8+ T cells targeting selected peptides that had been shown in an independent study of two
large cohorts to associate with control of viraemia [14]. This correlation was independent of
protective HLA class I alleles, which suggests that effective CD8+ T cell responses may be re-
stricted by a broader range of HLA class I alleles than previously suspected, as was also pro-
posed by Mothe et al [14]. While the viral regions that were defined as beneficial were
predominantly of low entropy, our regression analysis indicated that the magnitude of these re-
sponses accounted for a significantly greater proportion of the variation in viral inhibition than
entropy alone. The Gag component of these regions explained nearly two-thirds of the effect.
Interestingly, T cell responses to conserved elements peptides were weakly correlated with viral
inhibition and this effect was driven by only three of the seven conserved regions tested. This is
consistent with other studies showing that high population-level conservation per se does not
necessarily predict viral fitness and may reflect the presence of invariant regions that are
immunologically inert [27][45]. Collectively, these observations are not only reconcilable with
previously described associations between broad Gag-specific T cell responses and reduced
viral loads at the population level but also point to a mechanism that could explain them with
greater precision [10][14][6]. The greater the breadth of responses to Gag, the higher the prob-
ability of targeting the most vulnerable epitopes, even though there is also the possibility of tar-
geting the non-beneficial regions. The lack of responses to beneficial regions in some of the VC
studied is quite likely explained by the small sample size studied and / or the extended time of
untreated HIV infection which may have led to elimination of some of these T cell responses,
or possibly that these VC made responses to other critical epitopes that were not represented in
our peptide sets [32][46][47]. However, this does raise questions as to how long the effect of re-
sponses to beneficial regions lasts, in the face of ongoing viral escape. The rate of escape from
CD8+ T cell responses is determined by the net effect on viral fitness of all escape mutations
and is significantly slower in chronic than acute infection [48]. The association between the
prevalence of T cell responses to beneficial regions and population-level viral load was made in
chronically infected cohorts and suggests, therefore, that even though these beneficial re-
sponses may drive viral escape, the net effect is an overall impairment of viral fitness. This is
consistent with observations made by Boutwell et al. who showed that CD8+ T cell escape mu-
tations in HIV-1 Gag frequently impair viral fitness; many of the susceptible epitopes in their
study were located in the beneficial regions [49].
It is possible that we have overlooked functional characteristics of Gag-specific CD8+ T
cells such as the capacity to produce multiple cytokines simultaneously, as these have also been
associated with control of viraemia [50][51]. However, viral inhibition assays arguably provide
the most direct and complete measure of antiviral function, whereas the cytokines that are typi-
cally detected in assays of T cell polyfunctionality provide an indirect assessment. Our analysis
indicated that individuals with potent viral inhibitory responses are rare, as was reported by
others [24], and furthermore highlighted that responses to beneficial regions within the HIV
proteome are both infrequent and subdominant. This is consistent with a previous study that
showed infrequent targeting of epitopes in these regions in acute infection [32]. As spontane-
ous control of viraemia is itself a rare event, this provides further evidence that viral inhibitory
activity in vitro accurately reflects immune control in vivo. It also raises questions as to whether
long-term control or even clearance of infection can be achieved by vaccines that mimic prim-
ing by HIV. Responses elicited by the Ad5-HIV vaccine in HVTN 502 trial participants were
shown previously to be limited in breadth, with a bias towards variable regions [2][7]. Our ret-
rospective analysis of a subset of HVTN 502 vaccinees indicated preferential targeting of non-
beneficial regions, which was concerning given that the Gag/Pol/Nef immunogen contained
the majority of the previously described beneficial regions [14]. We observed a similar skewing
of responses in HIV-positive subjects who received a therapeutic MVA vaccine encoding the
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immunogen, HIVA, which included 9 of the identified beneficial regions within Gag. Newer
vaccine candidates such as Ad35-GRIN and Ad35-ENV, which comprise Gag, Reverse tran-
scriptase, Integrase and Nef and Env sequences, induced responses to a median of one Gag epi-
tope in HIV-uninfected healthy volunteers [40]. The common factor among these
immunogens is the inclusion of full or near-full-length Gag sequences. A non-human primate
study showed that full-length HIV immunogens induced responses to conserved regions that
were of similar breadth to those elicited by non-native conserved region immunogens [52]; by
contrast, Kulkarni et al. compared vaccination with p55 Gag and a conserved elements-only
immunogen and showed better recognition of conserved elements epitopes with the latter ap-
proach [28,53]. Taken together, these observations highlight the need for vaccines to overcome
natural immunodominance hierarchies in humans through the development of immunogens
that focus responses on specific critical regions of the viral proteome. Additional refinements,
such as inclusion of sequences that pre-empt predictable escape mutations, should also be con-
sidered [54]. Vaccine-mediated clearance of an AIDS virus infection in the non-human pri-
mate model was recently demonstrated for the first time with a persistent rhesus CMV SIV
vaccine [55,56][57]. It is noteworthy that the responses elicited were unique in terms of their
unprecedented breadth, absence of immunodominance and specificity for non-canonical viral
epitopes, although the immunogen comprised entire proteins. While this may reflect unusual
properties of the CMV vector and the specific mechanisms that contributed to virus eradica-
tion have yet to be resolved, such studies may provide vital lessons for human
vaccine development.
In summary, these data provide several new insights that should inform HIV vaccine design.
First, they suggest that induction of effective anti-HIV CD8+ T cell responses could be
achieved with an immunogen comprising only a few selected regions of the viral proteome. In
addition to the regions defined by Mothe et al., which were identified in chronically infected in-
dividuals, comprehensive analyses of responses that arise during acute / early HIV infection
may yield viral targets that are critical to early and sustained control [32][58]. Secondly, we
have identified a possible threshold for the magnitude of responses to these critical regions that
should be attained in order to have a meaningful impact on viral replication. Our analysis of re-
sponses to vaccination with Ad5 Gag/Pol/Nef in a small subset of HVTN 502 subjects prior to
HIV infection, together with other post-hoc studies, suggests that this is extremely unlikely to
be achieved using immunogens that comprise full-length proteins. Exclusion of irrelevant
decoy regions that when present, often induce immunodominant T cell responses, may be es-
sential to prevent the development of such non-protective responses. Finally, our previous ex-
perience with potent heterologous viral vector combinations has shown that it is feasible to
induce HIV-specific T cell responses in human subjects of the order of magnitude that we have
proposed here [8]; rationally designed immunogens that exploit these vectors should be priori-
tised for clinical development.
Methods
Ethics statement
Approval was obtained from the Oxford Tropical Research Ethics Committee for analysis of
anonymised PBMC samples that were made available to University of Oxford, UK by Fred
Hutchinson Cancer Research Center via a Material Transfer Agreement (‘HVTN 502/Merck
023—HVTN 503 Ancillary Study’) following approval of the study by HVTN Protocol Com-
mittee. The PBMC samples were gathered and obtained from a collection held by HVTN. Vire-
mic controllers (VC) were recruited at Duke University Medical Center with IRB approval and
after obtaining written informed consent.
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Study participants
The HVTN 502 and 503 studies have been described previously [1][9]. PBMC sampled from
36 HIV-positive HVTN 502 and 503 participants who were still naïve to ART 12 months after
HIV acquisition, with CD4+ cell counts>350 cells/μl, were provided through the HVTN 502
Oversight Committee. Plasma viral load data were provided by SCHARP and set-point was de-
termined using the method described by Fellay et al. [59]. Participants’ characteristics are given
in Table 1. Criteria for enrolment of VC were plasma viremia consistently<5000 copies/ml for
at least one year and a CD4+ cell count>400 cells/μl in the absence of ART. However, one sub-
ject was included despite a CD4+ cell count<400 cells μl because of viral loads consistently
<2280 copies/ml for 5 years prior to enrolment; this individual maintained viral loads<448
copies/ml during the study. Two subjects had transient viraemia>5000 copies/ml which was
subsequently spontaneously controlled. Patients’ characteristics are given in Table 2. All VC
had presumed clade B infection, due to the geographical location. Therapeutic vaccine trial par-
ticipants were patients with chronic HIV infection, receiving effective ART for at least 12
months, with CD4+ cell counts>350 cells/μl, who received two intramuscular immunisations
of MVA.HIVA 5x107 pfu 4 weeks apart [34][60]. HLA typing was performed as described pre-
viously [6].
Virus subtyping
Virus subtyping was performed by near full-length genome sequencing, as described previously
[61] or by bulk sequencing of p17 Gag and analysis using REGA HIV-1 & 2 Automated Sub-
typing Tool (Version 2.0) [62][63].
Virus isolates
HIV-1 isolates were obtained from the Programme EVA Centre for AIDS Reagents, National
Institute for Biological Standards and Control (NIBSC), a centre of the Health Protection
Agency, UK. The virus panel comprised two laboratory-adapted clade B isolates, BaL (CCR5-
tropic) and IIIB (CXCR4-tropic) and three primary isolates, ES X-1936 (clade C, CCR5-tropic),
92UG029 (clade A, CCR5 / CXCR4 dual-tropic) and RW93024 (clade A, CXCR-tropic). All
virus propagation was performed using primary CD4+ cells and 50% tissue culture infectious
doses (TCID50) for each virus was calculated as described previously [64].
Peptides
Clades B and C consensus peptides spanning the entire HIV proteome (15-mers overlapping
by 11 amino acids) were obtained from the NIH Aids Reagent Programme. 10mg/ml stocks
were stored at -80°C until required, then were diluted to generate working stocks. One or more
15-mer peptides that matched most closely the beneficial OLP described by Mothe et al. and
the CE peptides described by Kulkarni et al. were selected for use in Elispot assays [14][28] (Ta-
bles 3–5).
Viral inhibition assay
The viral inhibition assay has been described in detail elsewhere [16,65]. Briefly, CD8+ T cells
were isolated from cryopreserved PBMC by magnetic bead selection (Miltenyi Biotec) and re-
tained for use in IFN-γ Elispot assays. CD8-depleted cells (hereafter referred to as CD4+ T
cells) were stimulated with PHA (5 μg/mL) in RPMI 1640 medium supplemented with 10%
fetal calf serum (R10) for 3 days, washed, and infected with HIV-1 isolates at pre-determined
optimal MOI (National Institute for Biological Standards and Control, United Kingdom). To
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assess viral inhibition, HIV-superinfected CD4+ T cells (5 × 104) were cultured in triplicate in
R10 with interleukin 2 (20 IU/mL) in 96-well round-bottomed plates, alone or together with
unstimulated ex vivo CD8+ T cells, obtained by positive bead selection of PBMCs from a
second freshly thawed vial on day 3. CD8+ T cells were confirmed as>98% pure by staining
for CD3, CD8, and CD56. CD8+ and CD4+ T cells were co-cultured for 6 days for all virus
isolates except clade A2, for which the peak of virus replication is attained after 3 days [65].
CD8+/CD4+ ratios of 2:1, 1:1 and 1:10 were tested, according to cell availability. On the day of
harvest, cells were stained first with Aqua Live/Dead Fixable stain (Invitrogen), fixed with 1%
paraformaldehyde/20 μg/mL lysolecithin at RT, permeabilized with cold 50% methanol fol-
lowed by 0.1% Nonidet P-40, and finally stained with p24 antibody (KC-57-FITC; Beckman
Coulter) and antibodies to CD3, CD4, and CD8 (conjugated to APC-Cy7, PerCP, and APC,
respectively; BD Biosciences). Samples were acquired on a CyAn flow cytometer. Data were
analyzed using FlowJo software. Antiviral suppressive activity was expressed as percentage in-
hibition and determined as follows: [(fraction of p24 + cells in CD4 + T cells cultured alone)–
(fraction of p24 + in CD4+ T cells cultured with CD8+ cells)]/(fraction of p24 + cells in CD4 +
T cells cultured alone) × 100.
IFN-γ Elispot assay
Purified CD8+ T cells from the PBMC sample that was used to isolate CD4+ T cells for the
viral inhibition assay were tested in IFN-γ Elispot assays with pools of beneficial or CE peptides
(final concentration 2μg/ml) as described previously [16]. Mapping of responses to epitopes in
the Gag component of the HIVA immunogen was performed using PBMC sampled pre- and 2
or 4 weeks post-vaccination, with overlapping 15-mer peptides (final concentration 4μg/ml)
spanning the entire immunogen sequence, with confirmation using optimal 8–10-mer peptides
where available [60]. Elispot assays with CD8-depleted PBMC were performed to confirm that
these responses were CD8+ T cell-mediated. In selected assays, CD8+ T cells were recovered
from the Elispot plate after overnight incubation with peptides, washed and cultured (2x106/ml)
in R10 medium (RPMI with 10% fetal calf serum) plus IL-7 (25ng/ml). Cultures were supple-
mented with IL-2 (1.8 x103 units/ml) on day 3 and R10/IL-7/IL-2 medium was replaced on day
7. Cells were starved of IL-2 for 30 hours on day 10 and then used in cultured IFN-γ Elispot as-
says with individual peptides (2μg/ml).
Intracellular cytokine assay
Intracellular cytokine staining was performed as described previously, typically at the second
visit after HIV infection had been confirmed [66][2].
Statistical analysis
Group comparisons were performed using the MannWhitney test and correlations were inves-
tigated by determination of Spearman’s rank coefficient, using Graphpad Prism software, ver-
sion 6. Models to explore predictors of inter-subject variation in viral inhibition by CD8+ T
cells were tested using univariate and multivariable linear regression. Analyses were performed
using SPSS version 22.
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